64,038 Johnson & Johnson $JNJ Shares Acquired by Vise Technologies Inc.

Vise Technologies Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 30.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 275,901 shares of the company’s stock after acquiring an additional 64,038 shares during the quarter. Vise Technologies Inc.’s holdings in Johnson & Johnson were worth $73,042,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Outlook Capital Management LLC acquired a new position in Johnson & Johnson in the second quarter valued at $28,000. Matrix Trust Co raised its holdings in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $43,000. Hanseatic Management Services Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $52,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson during the third quarter worth about $56,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.9%

NYSE JNJ opened at $270.81 on Tuesday. The stock has a market capitalization of $651.93 billion, a P/E ratio of 41.03, a P/E/G ratio of 2.68 and a beta of 0.21. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The firm has a 50-day moving average price of $265.74 and a 200 day moving average price of $247.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The firm’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 64,515 shares of company stock worth $17,271,766 over the last three months. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Royal Bank Of Canada reduced their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. HSBC increased their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Scotiabank reissued an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Bank of America restated a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $275.92.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.